Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
719.00    -5.00 (-0.69%)
Bid:
719.00
Ask:
745.00
Spread: 26.00 (3.616%)
Market Cap: £48.89m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Director/PDMR Shareholding

12 Feb 2018 07:00

RNS Number : 5133E
Hemogenyx Pharmaceuticals PLC
12 February 2018
 

Hemogenyx Pharmaceuticals Plc 

("Hemogenyx" or the "Company")

 

Director / PDMR Shareholding

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 9 February 2018 Adrian Beeston, Non-Executive Director, purchased 200,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 2.1p per share. Following this transaction Mr Beeston now has an interest in 6,331,969 Ordinary Shares, representing approximately 1.78 per cent. of the Company's issued share capital.

 

The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Adrian Beeston

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-executive Director

 

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hemogenyx Pharmaceuticals Plc

b)

 

LEI

 

 

n/a

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

Identification code

ISIN GB00BYX3WZ24

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

2.1p

200,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

 N/A - single transaction

- Price

e)

 

Date of the transaction

 

 

9 February 2018

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIGDDDDGBGIC
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM
29th May 20269:18 amRNSGrant of Options and Extension of Warrant Term
30th Apr 20264:04 pmRNSFinal Results
28th Apr 20267:00 amRNSInstitutional Fundraise
14th Apr 20267:00 amRNSAnnual IND Report with FDA
31st Mar 20261:22 pmRNSTech Transfer Completion and Clinical Trial Update
27th Feb 20268:10 amRNSTotal Voting Rights
24th Feb 20267:00 amRNSHolding(s) in Company
23rd Feb 20267:00 amRNSExercise of Warrants and Issue of Equity
10th Feb 20263:52 pmRNSIssue of Equity - Correction
10th Feb 20267:00 amRNSIssue of Equity
30th Jan 20267:00 amRNSTotal Voting Rights
12th Jan 20267:00 amRNSHolding(s) in Company
22nd Dec 20258:00 amRNSUpdate on Admission of Shares
18th Dec 20257:00 amRNSIssue of Equity
8th Dec 202512:48 pmRNSHolding(s) in Company
28th Nov 20257:00 amRNSTotal Voting Rights
19th Nov 202511:47 amRNSPublication of Prospectus
29th Oct 20257:00 amRNSClinical Trial Update and Grant of Share Awards
6th Oct 20257:00 amRNSClearance to Initiate Pediatric Enrolment
30th Sep 20257:00 amRNSHalf-year Report
30th Sep 20257:00 amRNSTotal Voting Rights
23rd Sep 20257:00 amRNSHemogenyx Signs Letter of Intent
18th Sep 20251:16 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSThird Patient Safety
11th Sep 20257:00 amRNS-RInvitation to Participate at DCNY Summit
8th Sep 20257:00 amRNSManufacturing Partnership with Made Scientific
5th Sep 20257:00 amRNSExercise of Warrants and Issue of Equity
3rd Sep 20251:57 pmRNSExercise of Warrants and Issue of Equity
1st Sep 20253:06 pmRNSIssue of convertible loan notes
29th Aug 20257:00 amRNSResult of Audit Tender
26th Aug 202511:44 amRNSHemogenyx raises £570,000 and Director's Dealing
15th Aug 20257:00 amRNSThird Patient Treated with HG-CT-1 CAR-T Therapy
31st Jul 20257:00 amRNSTotal Voting Rights
29th Jul 20258:00 amRNSPlacing to Raise £250,000 and Director’s Dealing
16th Jul 20257:00 amRNSHemogenyx Awarded Grant
30th Jun 20257:00 amRNSTotal Voting Rights
17th Jun 20257:00 amRNSClearance to Proceed with Pediatric Expansion
3rd Jun 20252:02 pmRNSPlacing to Raise £451,250 and Director’s Dealing
3rd Jun 20257:00 amRNSSecond Patient Passes Initial Safety Tests
30th May 20253:14 pmRNSTotal Voting Rights
29th May 20252:06 pmRNSResult of AGM
14th May 20257:00 amRNS-RPediatric Amendment to Clinical Protocol
13th May 20257:00 amRNSAGM Correction
8th May 20257:00 amRNSPlacing to Raise £451,250 and Director’s Dealing
2nd May 20254:24 pmRNSNotice of AGM
2nd May 20257:00 amRNSSecond Patient Treated with HG-CT-1 CAR-T Therapy
28th Apr 20257:00 amRNSFinal Results
3rd Apr 20257:00 amRNS-RFDA Annual Report
31st Mar 20257:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.